瑞普生物(300119.SZ):控股子公司取得新獸藥註冊證書
格隆匯11月5日丨瑞普生物(300119.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》的規定,公司控股子公司廣州市華南農大生物藥品有限公司近日獲得由農業農村部核發的《新獸藥註冊證書》,新獸藥名稱為重組禽流感病毒(H5+H7)三價滅活疫苗(H5N2rSD57株+rFJ56株,H7N9rGD76株)。
“重組禽流感病毒(H5+H7)三價滅活疫苗(H5N2rSD57株+rFJ56株,H7N9rGD76株)”選用全新H5、H7亞型流行代表毒株作為供體,採用先進反向遺傳操作技術拯救獲得,能夠有效提供針對Clade2.3.2.1d和Clade2.3.4.4d的H5亞型高致病性禽流感病毒以及H7N9亞型高致病性禽流感病毒等流行毒株攻擊的保護,有效預防H5N6亞型和H7N9亞型高致病性禽流感病毒的感染,具有全禽源、高抗體、高交叉保護、高安全性等特點,是中國兩種用於高致病性禽流感防控的疫苗之一。
該產品的成功研製為我國防控H5亞型和H7亞型高致病性禽流感提供瞭解決方案,為我國養禽業健康發展提供了有效的技術支撐,有利於進一步提升公司市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.